Review



murf2 antibody  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Bio-Techne corporation murf2 antibody
    Murf2 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murf2 antibody/product/Bio-Techne corporation
    Average 90 stars, based on 2 article reviews
    murf2 antibody - by Bioz Stars, 2026-05
    90/100 stars

    Images



    Similar Products

    90
    Bio-Techne corporation murf2 antibody
    Murf2 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murf2 antibody/product/Bio-Techne corporation
    Average 90 stars, based on 1 article reviews
    murf2 antibody - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Myomedix GmbH murf2 antibody
    Murf2 Antibody, supplied by Myomedix GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murf2 antibody/product/Myomedix GmbH
    Average 90 stars, based on 1 article reviews
    murf2 antibody - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    92
    Santa Cruz Biotechnology mouse monoclonal anti murf2
    Mouse Monoclonal Anti Murf2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti murf2/product/Santa Cruz Biotechnology
    Average 92 stars, based on 1 article reviews
    mouse monoclonal anti murf2 - by Bioz Stars, 2026-05
    92/100 stars
      Buy from Supplier

    90
    Novus Biologicals rabbit antibody
    Rabbit Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit antibody/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    rabbit antibody - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Novus Biologicals trim55
    Figure 1. <t>TRIM55</t> is downregulated in HCC tissues and is associated with prognosis of HCC patients. (A) IHC detected expression of TRIM55 in HCC tissues and neighboring tissues. Representative photos at 200× and 400×. The level of TRIM55 expression between HCC tissues and neighbor tissues was analyzed and shown as a pie chart. (B, C) the relationship between overall survival and TRIM55 expression was analyzed by Kaplan-Meier analysis, and the follow-up data were collected by ourselves (B) or TCGA database (C).
    Trim55, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trim55/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    trim55 - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Novus Biologicals human trim55 antibody
    Figure 1. <t>TRIM55</t> is downregulated in HCC tissues and is associated with prognosis of HCC patients. (A) IHC detected expression of TRIM55 in HCC tissues and neighboring tissues. Representative photos at 200× and 400×. The level of TRIM55 expression between HCC tissues and neighbor tissues was analyzed and shown as a pie chart. (B, C) the relationship between overall survival and TRIM55 expression was analyzed by Kaplan-Meier analysis, and the follow-up data were collected by ourselves (B) or TCGA database (C).
    Human Trim55 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human trim55 antibody/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    human trim55 antibody - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    92
    Santa Cruz Biotechnology murf2
    Fig. 1 MuRF1 and <t>MuRF2</t> are highly induced during skeletal muscle regeneration. (a) MuRF1, MuRF2 and Mafbx/Atrogin‐1 immunoblots 3 and 10 days after TA CTX injury. Sarcomeric actin is a loading control. (b‐g) Immunolocalization of MuRF1 and (j‐o) MuRF2, 3 and 10 days after CTX injury in TA muscle. In h‐i and p‐q, primary antibodies were not used in the assay. Immunodetection of laminin (green) was used to outline muscle fibers. (h‐i and p‐q) No primary antibodies were added to the assay. Images were obtained with a fluorescence microscope and a 40x air medium objective. Bar, 50µm
    Murf2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murf2/product/Santa Cruz Biotechnology
    Average 92 stars, based on 1 article reviews
    murf2 - by Bioz Stars, 2026-05
    92/100 stars
      Buy from Supplier

    Image Search Results


    Figure 1. TRIM55 is downregulated in HCC tissues and is associated with prognosis of HCC patients. (A) IHC detected expression of TRIM55 in HCC tissues and neighboring tissues. Representative photos at 200× and 400×. The level of TRIM55 expression between HCC tissues and neighbor tissues was analyzed and shown as a pie chart. (B, C) the relationship between overall survival and TRIM55 expression was analyzed by Kaplan-Meier analysis, and the follow-up data were collected by ourselves (B) or TCGA database (C).

    Journal: Medical Science Monitor

    Article Title: Overexpression of Tripartite Motif Conaining 55 (TRIM55) Inhibits Migration and Invasion of Hepatocellular Carcinoma (HCC) Cells via Epithelial-Mesenchymal Transition and Matrix Metalloproteinase-2 (MMP2)

    doi: 10.12659/msm.910984

    Figure Lengend Snippet: Figure 1. TRIM55 is downregulated in HCC tissues and is associated with prognosis of HCC patients. (A) IHC detected expression of TRIM55 in HCC tissues and neighboring tissues. Representative photos at 200× and 400×. The level of TRIM55 expression between HCC tissues and neighbor tissues was analyzed and shown as a pie chart. (B, C) the relationship between overall survival and TRIM55 expression was analyzed by Kaplan-Meier analysis, and the follow-up data were collected by ourselves (B) or TCGA database (C).

    Article Snippet: The primary antibodies were as follows: TRIM55 (Novus, NBP2-33691, dilution 1/1000), E-cadherin and Vimentin (Cell Signaling Technology, (EMT) Antibody Sampler Kit #9782, dilution 1/1000), and MMP2 (Proteintech, 10373-2-AP, dilution 1/1000), and the internal control was GAPDH (Abcam Biotechnology, Cambridge, UK, dilution 1/1000).

    Techniques: Expressing

    Figure 2. TRIM55 overexpression in HCC cell lines was constructed. (A) Western blot was used to verify transfection efficiency at the protein level. GAPDH was used as internal control. (B) RT-PCR was used to verify transfection efficiency at the mRNA level, *** p<0.0001.

    Journal: Medical Science Monitor

    Article Title: Overexpression of Tripartite Motif Conaining 55 (TRIM55) Inhibits Migration and Invasion of Hepatocellular Carcinoma (HCC) Cells via Epithelial-Mesenchymal Transition and Matrix Metalloproteinase-2 (MMP2)

    doi: 10.12659/msm.910984

    Figure Lengend Snippet: Figure 2. TRIM55 overexpression in HCC cell lines was constructed. (A) Western blot was used to verify transfection efficiency at the protein level. GAPDH was used as internal control. (B) RT-PCR was used to verify transfection efficiency at the mRNA level, *** p<0.0001.

    Article Snippet: The primary antibodies were as follows: TRIM55 (Novus, NBP2-33691, dilution 1/1000), E-cadherin and Vimentin (Cell Signaling Technology, (EMT) Antibody Sampler Kit #9782, dilution 1/1000), and MMP2 (Proteintech, 10373-2-AP, dilution 1/1000), and the internal control was GAPDH (Abcam Biotechnology, Cambridge, UK, dilution 1/1000).

    Techniques: Over Expression, Construct, Western Blot, Transfection, Control, Reverse Transcription Polymerase Chain Reaction

    Figure 3. Overexpression of TRIM55 inhibits migration and invasion of HCC cells. (A, B) Cell migration and invasion ability were detected by Transwell assay in HCC cells with TRIM55 overexpression and negative control. All experiments were repeated 3 times. *** p<0.0001

    Journal: Medical Science Monitor

    Article Title: Overexpression of Tripartite Motif Conaining 55 (TRIM55) Inhibits Migration and Invasion of Hepatocellular Carcinoma (HCC) Cells via Epithelial-Mesenchymal Transition and Matrix Metalloproteinase-2 (MMP2)

    doi: 10.12659/msm.910984

    Figure Lengend Snippet: Figure 3. Overexpression of TRIM55 inhibits migration and invasion of HCC cells. (A, B) Cell migration and invasion ability were detected by Transwell assay in HCC cells with TRIM55 overexpression and negative control. All experiments were repeated 3 times. *** p<0.0001

    Article Snippet: The primary antibodies were as follows: TRIM55 (Novus, NBP2-33691, dilution 1/1000), E-cadherin and Vimentin (Cell Signaling Technology, (EMT) Antibody Sampler Kit #9782, dilution 1/1000), and MMP2 (Proteintech, 10373-2-AP, dilution 1/1000), and the internal control was GAPDH (Abcam Biotechnology, Cambridge, UK, dilution 1/1000).

    Techniques: Over Expression, Migration, Transwell Assay, Negative Control

    Figure 4. Overexpression of TRIM55 inhibits migration and invasion of HCC cells through EMT and MMP2. (A) IF was used to detect expression of E-cadherin and Vimentin in HCC cells with TRIM55 overexpression and negative control. (B) Western blot was used to detect expression of E-cadherin, Vimentin, and MMP2 in HCC cells with TRIM55 overexpression and negative control. GAPDH was used as internal control.

    Journal: Medical Science Monitor

    Article Title: Overexpression of Tripartite Motif Conaining 55 (TRIM55) Inhibits Migration and Invasion of Hepatocellular Carcinoma (HCC) Cells via Epithelial-Mesenchymal Transition and Matrix Metalloproteinase-2 (MMP2)

    doi: 10.12659/msm.910984

    Figure Lengend Snippet: Figure 4. Overexpression of TRIM55 inhibits migration and invasion of HCC cells through EMT and MMP2. (A) IF was used to detect expression of E-cadherin and Vimentin in HCC cells with TRIM55 overexpression and negative control. (B) Western blot was used to detect expression of E-cadherin, Vimentin, and MMP2 in HCC cells with TRIM55 overexpression and negative control. GAPDH was used as internal control.

    Article Snippet: The primary antibodies were as follows: TRIM55 (Novus, NBP2-33691, dilution 1/1000), E-cadherin and Vimentin (Cell Signaling Technology, (EMT) Antibody Sampler Kit #9782, dilution 1/1000), and MMP2 (Proteintech, 10373-2-AP, dilution 1/1000), and the internal control was GAPDH (Abcam Biotechnology, Cambridge, UK, dilution 1/1000).

    Techniques: Over Expression, Migration, Expressing, Negative Control, Western Blot, Control

    Figure 1. TRIM55 is downregulated in HCC tissues and is associated with prognosis of HCC patients. (A) IHC detected expression of TRIM55 in HCC tissues and neighboring tissues. Representative photos at 200× and 400×. The level of TRIM55 expression between HCC tissues and neighbor tissues was analyzed and shown as a pie chart. (B, C) the relationship between overall survival and TRIM55 expression was analyzed by Kaplan-Meier analysis, and the follow-up data were collected by ourselves (B) or TCGA database (C).

    Journal: Medical Science Monitor

    Article Title: Overexpression of Tripartite Motif Conaining 55 (TRIM55) Inhibits Migration and Invasion of Hepatocellular Carcinoma (HCC) Cells via Epithelial-Mesenchymal Transition and Matrix Metalloproteinase-2 (MMP2)

    doi: 10.12659/msm.910984

    Figure Lengend Snippet: Figure 1. TRIM55 is downregulated in HCC tissues and is associated with prognosis of HCC patients. (A) IHC detected expression of TRIM55 in HCC tissues and neighboring tissues. Representative photos at 200× and 400×. The level of TRIM55 expression between HCC tissues and neighbor tissues was analyzed and shown as a pie chart. (B, C) the relationship between overall survival and TRIM55 expression was analyzed by Kaplan-Meier analysis, and the follow-up data were collected by ourselves (B) or TCGA database (C).

    Article Snippet: After exposure to 5% BSA for 30 min, all tissues were incubated with rabbit antibody to human TRIM55 antibody (Novus, NBP2-33691, dilution 1/200) overnight at 4°C.

    Techniques: Expressing

    Figure 2. TRIM55 overexpression in HCC cell lines was constructed. (A) Western blot was used to verify transfection efficiency at the protein level. GAPDH was used as internal control. (B) RT-PCR was used to verify transfection efficiency at the mRNA level, *** p<0.0001.

    Journal: Medical Science Monitor

    Article Title: Overexpression of Tripartite Motif Conaining 55 (TRIM55) Inhibits Migration and Invasion of Hepatocellular Carcinoma (HCC) Cells via Epithelial-Mesenchymal Transition and Matrix Metalloproteinase-2 (MMP2)

    doi: 10.12659/msm.910984

    Figure Lengend Snippet: Figure 2. TRIM55 overexpression in HCC cell lines was constructed. (A) Western blot was used to verify transfection efficiency at the protein level. GAPDH was used as internal control. (B) RT-PCR was used to verify transfection efficiency at the mRNA level, *** p<0.0001.

    Article Snippet: After exposure to 5% BSA for 30 min, all tissues were incubated with rabbit antibody to human TRIM55 antibody (Novus, NBP2-33691, dilution 1/200) overnight at 4°C.

    Techniques: Over Expression, Construct, Western Blot, Transfection, Control, Reverse Transcription Polymerase Chain Reaction

    Figure 3. Overexpression of TRIM55 inhibits migration and invasion of HCC cells. (A, B) Cell migration and invasion ability were detected by Transwell assay in HCC cells with TRIM55 overexpression and negative control. All experiments were repeated 3 times. *** p<0.0001

    Journal: Medical Science Monitor

    Article Title: Overexpression of Tripartite Motif Conaining 55 (TRIM55) Inhibits Migration and Invasion of Hepatocellular Carcinoma (HCC) Cells via Epithelial-Mesenchymal Transition and Matrix Metalloproteinase-2 (MMP2)

    doi: 10.12659/msm.910984

    Figure Lengend Snippet: Figure 3. Overexpression of TRIM55 inhibits migration and invasion of HCC cells. (A, B) Cell migration and invasion ability were detected by Transwell assay in HCC cells with TRIM55 overexpression and negative control. All experiments were repeated 3 times. *** p<0.0001

    Article Snippet: After exposure to 5% BSA for 30 min, all tissues were incubated with rabbit antibody to human TRIM55 antibody (Novus, NBP2-33691, dilution 1/200) overnight at 4°C.

    Techniques: Over Expression, Migration, Transwell Assay, Negative Control

    Figure 4. Overexpression of TRIM55 inhibits migration and invasion of HCC cells through EMT and MMP2. (A) IF was used to detect expression of E-cadherin and Vimentin in HCC cells with TRIM55 overexpression and negative control. (B) Western blot was used to detect expression of E-cadherin, Vimentin, and MMP2 in HCC cells with TRIM55 overexpression and negative control. GAPDH was used as internal control.

    Journal: Medical Science Monitor

    Article Title: Overexpression of Tripartite Motif Conaining 55 (TRIM55) Inhibits Migration and Invasion of Hepatocellular Carcinoma (HCC) Cells via Epithelial-Mesenchymal Transition and Matrix Metalloproteinase-2 (MMP2)

    doi: 10.12659/msm.910984

    Figure Lengend Snippet: Figure 4. Overexpression of TRIM55 inhibits migration and invasion of HCC cells through EMT and MMP2. (A) IF was used to detect expression of E-cadherin and Vimentin in HCC cells with TRIM55 overexpression and negative control. (B) Western blot was used to detect expression of E-cadherin, Vimentin, and MMP2 in HCC cells with TRIM55 overexpression and negative control. GAPDH was used as internal control.

    Article Snippet: After exposure to 5% BSA for 30 min, all tissues were incubated with rabbit antibody to human TRIM55 antibody (Novus, NBP2-33691, dilution 1/200) overnight at 4°C.

    Techniques: Over Expression, Migration, Expressing, Negative Control, Western Blot, Control

    Fig. 1 MuRF1 and MuRF2 are highly induced during skeletal muscle regeneration. (a) MuRF1, MuRF2 and Mafbx/Atrogin‐1 immunoblots 3 and 10 days after TA CTX injury. Sarcomeric actin is a loading control. (b‐g) Immunolocalization of MuRF1 and (j‐o) MuRF2, 3 and 10 days after CTX injury in TA muscle. In h‐i and p‐q, primary antibodies were not used in the assay. Immunodetection of laminin (green) was used to outline muscle fibers. (h‐i and p‐q) No primary antibodies were added to the assay. Images were obtained with a fluorescence microscope and a 40x air medium objective. Bar, 50µm

    Journal: JCSM Rapid Communications

    Article Title: MuRF1 and MuRF2 are key players in skeletal muscle regeneration involving myogenic deficit and deregulation of the chromatin-remodeling complex

    doi: 10.1002/j.2617-1619.2019.tb00010.x

    Figure Lengend Snippet: Fig. 1 MuRF1 and MuRF2 are highly induced during skeletal muscle regeneration. (a) MuRF1, MuRF2 and Mafbx/Atrogin‐1 immunoblots 3 and 10 days after TA CTX injury. Sarcomeric actin is a loading control. (b‐g) Immunolocalization of MuRF1 and (j‐o) MuRF2, 3 and 10 days after CTX injury in TA muscle. In h‐i and p‐q, primary antibodies were not used in the assay. Immunodetection of laminin (green) was used to outline muscle fibers. (h‐i and p‐q) No primary antibodies were added to the assay. Images were obtained with a fluorescence microscope and a 40x air medium objective. Bar, 50µm

    Article Snippet: The primary antibodies used for western blot were: (1) MuRF1 and (2) MuRF2 [27, 32]; (2) Atrogin/Mafbx‐1 (Cat#AP2041, ECM Biosciences); (3) Myf‐5 (Cat#sc‐302, Santa Cruz); (4) Myogenin (Cat#ab1835, Abcam); (5) sarcomeric actin (Cat#M0847, Dako); (6) GAPDH (Cat# 2118, CellSignaling), (7) FHL2 (Cat# A300‐332A, Bethyl Laboratories); (8) MARP2; (9) BAF57 (Cat#Abd52, Millipore).

    Techniques: Western Blot, Control, Immunodetection, Fluorescence, Microscopy

    Fig. 2 Combined deletion of MuRF1 and MuRF2 causes deficient skeletal muscle regeneration. TA muscles from WT (a and e), from MuRF1 KOs (b and f), MuRF2 KOs (c and g), or from MuRF1&2 dKOs (d and h) were CTX injured and histologically analyzed 3 or 10 days later, respectively. We also histologically analyzed WT and MuRF1&2 dKO mice at 28 days (i and j respectively) after CTX. TA from MuRF1&2 dKO mice presented indications of defective regeneration in all time points analyzed (d, h and j, see text for detailed description). Bar, 20µm. (k) Average density of necrotic fibers in WT and MuRF1&2 dKO 24h after CTX injury; error bars indicate standard deviations (N=3)

    Journal: JCSM Rapid Communications

    Article Title: MuRF1 and MuRF2 are key players in skeletal muscle regeneration involving myogenic deficit and deregulation of the chromatin-remodeling complex

    doi: 10.1002/j.2617-1619.2019.tb00010.x

    Figure Lengend Snippet: Fig. 2 Combined deletion of MuRF1 and MuRF2 causes deficient skeletal muscle regeneration. TA muscles from WT (a and e), from MuRF1 KOs (b and f), MuRF2 KOs (c and g), or from MuRF1&2 dKOs (d and h) were CTX injured and histologically analyzed 3 or 10 days later, respectively. We also histologically analyzed WT and MuRF1&2 dKO mice at 28 days (i and j respectively) after CTX. TA from MuRF1&2 dKO mice presented indications of defective regeneration in all time points analyzed (d, h and j, see text for detailed description). Bar, 20µm. (k) Average density of necrotic fibers in WT and MuRF1&2 dKO 24h after CTX injury; error bars indicate standard deviations (N=3)

    Article Snippet: The primary antibodies used for western blot were: (1) MuRF1 and (2) MuRF2 [27, 32]; (2) Atrogin/Mafbx‐1 (Cat#AP2041, ECM Biosciences); (3) Myf‐5 (Cat#sc‐302, Santa Cruz); (4) Myogenin (Cat#ab1835, Abcam); (5) sarcomeric actin (Cat#M0847, Dako); (6) GAPDH (Cat# 2118, CellSignaling), (7) FHL2 (Cat# A300‐332A, Bethyl Laboratories); (8) MARP2; (9) BAF57 (Cat#Abd52, Millipore).

    Techniques: Muscles

    Fig.3 Simultaneous deletion of MuRF1 and MuRF2 decreases the number of cells positive to Pax7 and Myod. TA muscles from WT, or MuRF1&2 dKO mice were investigated by immunofluorescence 3 (a‐d and j‐m) or 10 days (e‐h and n‐q) after CTX injections. Immunolocalization and percentage of positive eMHC positive myofibers was also determined (u). DAPI (blue), Pax7 and Myod (red), laminin (green) and eMHC (green). Images were obtained with a fluorescence microscope and a 40x air medium objective. Large bar, 50 µm, small bar 10 µm

    Journal: JCSM Rapid Communications

    Article Title: MuRF1 and MuRF2 are key players in skeletal muscle regeneration involving myogenic deficit and deregulation of the chromatin-remodeling complex

    doi: 10.1002/j.2617-1619.2019.tb00010.x

    Figure Lengend Snippet: Fig.3 Simultaneous deletion of MuRF1 and MuRF2 decreases the number of cells positive to Pax7 and Myod. TA muscles from WT, or MuRF1&2 dKO mice were investigated by immunofluorescence 3 (a‐d and j‐m) or 10 days (e‐h and n‐q) after CTX injections. Immunolocalization and percentage of positive eMHC positive myofibers was also determined (u). DAPI (blue), Pax7 and Myod (red), laminin (green) and eMHC (green). Images were obtained with a fluorescence microscope and a 40x air medium objective. Large bar, 50 µm, small bar 10 µm

    Article Snippet: The primary antibodies used for western blot were: (1) MuRF1 and (2) MuRF2 [27, 32]; (2) Atrogin/Mafbx‐1 (Cat#AP2041, ECM Biosciences); (3) Myf‐5 (Cat#sc‐302, Santa Cruz); (4) Myogenin (Cat#ab1835, Abcam); (5) sarcomeric actin (Cat#M0847, Dako); (6) GAPDH (Cat# 2118, CellSignaling), (7) FHL2 (Cat# A300‐332A, Bethyl Laboratories); (8) MARP2; (9) BAF57 (Cat#Abd52, Millipore).

    Techniques: Muscles, Immunofluorescence, Fluorescence, Microscopy

    Fig. 4 Simultaneous deletion of MuRF1 and MuRF2 causes decreased protein expression of myogenic factors and increased apoptosis. (a) Western blots for Myogenin, Myf‐5, FHL2, MARP2 and GAPDH in TA of MuRF1&2 dKO animals 3 and 10 days after CTX injury and silver staining showing even protein loading. Fluorescence images showing apoptotic nuclei by TUNEL assay in WT (b‐d and h‐j) and MuRF1&2 dKO (e‐g and k‐m) muscles 3 (b‐g) and 10 (h‐ m) days after CTX injury. Images were obtained with a fluorescence microscope and a 40x air medium objective. Bar, 30 µm. (n) Percentage of apoptotic nuclei in WT and MuRF1&2 dKO muscles 3 and 10 days after CTX injury

    Journal: JCSM Rapid Communications

    Article Title: MuRF1 and MuRF2 are key players in skeletal muscle regeneration involving myogenic deficit and deregulation of the chromatin-remodeling complex

    doi: 10.1002/j.2617-1619.2019.tb00010.x

    Figure Lengend Snippet: Fig. 4 Simultaneous deletion of MuRF1 and MuRF2 causes decreased protein expression of myogenic factors and increased apoptosis. (a) Western blots for Myogenin, Myf‐5, FHL2, MARP2 and GAPDH in TA of MuRF1&2 dKO animals 3 and 10 days after CTX injury and silver staining showing even protein loading. Fluorescence images showing apoptotic nuclei by TUNEL assay in WT (b‐d and h‐j) and MuRF1&2 dKO (e‐g and k‐m) muscles 3 (b‐g) and 10 (h‐ m) days after CTX injury. Images were obtained with a fluorescence microscope and a 40x air medium objective. Bar, 30 µm. (n) Percentage of apoptotic nuclei in WT and MuRF1&2 dKO muscles 3 and 10 days after CTX injury

    Article Snippet: The primary antibodies used for western blot were: (1) MuRF1 and (2) MuRF2 [27, 32]; (2) Atrogin/Mafbx‐1 (Cat#AP2041, ECM Biosciences); (3) Myf‐5 (Cat#sc‐302, Santa Cruz); (4) Myogenin (Cat#ab1835, Abcam); (5) sarcomeric actin (Cat#M0847, Dako); (6) GAPDH (Cat# 2118, CellSignaling), (7) FHL2 (Cat# A300‐332A, Bethyl Laboratories); (8) MARP2; (9) BAF57 (Cat#Abd52, Millipore).

    Techniques: Expressing, Western Blot, Silver Staining, Fluorescence, TUNEL Assay, Muscles, Microscopy

    Fig. 5 Simultaneous deletion of MuRF1 and MuRF2 time‐shifts the localization/expression of β‐catenin during regeneration. TA muscles from WT (a‐e and k‐o), or MuRF1&2 dKO mice (f‐j and p‐t) were studied by immunofluorescence 3 (a‐j) or 10 days (k‐t) after CTX injections. DAPI (blue), β‐catenin (red), MyoD (green) and laminin (white). Arrows indicate nuclei simultaneously positive to MyoD, B‐catenin and Dapi. Arrow heads indicate non‐nuclear β‐catenin labeling. Images were obtained with a fluorescence microscope and a 40x air medium objective. Bar, 20 µm. (u) Number of β‐catenin positive cells/mm 2 in WT and MuRF1&2 dKO TA muscles. ***p<0.001 vs WT

    Journal: JCSM Rapid Communications

    Article Title: MuRF1 and MuRF2 are key players in skeletal muscle regeneration involving myogenic deficit and deregulation of the chromatin-remodeling complex

    doi: 10.1002/j.2617-1619.2019.tb00010.x

    Figure Lengend Snippet: Fig. 5 Simultaneous deletion of MuRF1 and MuRF2 time‐shifts the localization/expression of β‐catenin during regeneration. TA muscles from WT (a‐e and k‐o), or MuRF1&2 dKO mice (f‐j and p‐t) were studied by immunofluorescence 3 (a‐j) or 10 days (k‐t) after CTX injections. DAPI (blue), β‐catenin (red), MyoD (green) and laminin (white). Arrows indicate nuclei simultaneously positive to MyoD, B‐catenin and Dapi. Arrow heads indicate non‐nuclear β‐catenin labeling. Images were obtained with a fluorescence microscope and a 40x air medium objective. Bar, 20 µm. (u) Number of β‐catenin positive cells/mm 2 in WT and MuRF1&2 dKO TA muscles. ***p<0.001 vs WT

    Article Snippet: The primary antibodies used for western blot were: (1) MuRF1 and (2) MuRF2 [27, 32]; (2) Atrogin/Mafbx‐1 (Cat#AP2041, ECM Biosciences); (3) Myf‐5 (Cat#sc‐302, Santa Cruz); (4) Myogenin (Cat#ab1835, Abcam); (5) sarcomeric actin (Cat#M0847, Dako); (6) GAPDH (Cat# 2118, CellSignaling), (7) FHL2 (Cat# A300‐332A, Bethyl Laboratories); (8) MARP2; (9) BAF57 (Cat#Abd52, Millipore).

    Techniques: Expressing, Muscles, Immunofluorescence, Labeling, Fluorescence, Microscopy

    Fig. 6 siRNA knock down of MuRF1 and MuRF2 reduce myogenesis. (a‐d) Phase contrast micrographs of primary myoblast culture 2 days after induction of differentiation. Images were taken with a 4x objective. Cells were siRNA knocked down for MuRF1 (b), MuRF2 (c) and MuRF1 and MuRF2 combined (d). (a) Arrowheads indicate the normal differentiation pattern generating myotubes. (b‐d) Arrows indicate a severe differentiation deficit. (e) Fusion index of siRNA knocked down cells. (f) Myotube area of siRNA knocked down cells. (g) Number of myotube by field of siRNA knocked down cells. The fusion index was calculated as the ratio of the nuclei number in myotubes with two or more nuclei versus the total number of nuclei. Ten representative images per sample were scored for myotube number and area occupied by myotubes relative to the total area ( a p<0.05 vs Control). Fluorescence images showing reduced expression of eMHC after siRNA knock down for MuRF1 (k‐m) MuRF2 (n‐p) and MuRF1 and MuRF2 combined (q‐s) compared to control (h‐j). Images were obtained with a fluorescence microscope. Bars, 20 µm

    Journal: JCSM Rapid Communications

    Article Title: MuRF1 and MuRF2 are key players in skeletal muscle regeneration involving myogenic deficit and deregulation of the chromatin-remodeling complex

    doi: 10.1002/j.2617-1619.2019.tb00010.x

    Figure Lengend Snippet: Fig. 6 siRNA knock down of MuRF1 and MuRF2 reduce myogenesis. (a‐d) Phase contrast micrographs of primary myoblast culture 2 days after induction of differentiation. Images were taken with a 4x objective. Cells were siRNA knocked down for MuRF1 (b), MuRF2 (c) and MuRF1 and MuRF2 combined (d). (a) Arrowheads indicate the normal differentiation pattern generating myotubes. (b‐d) Arrows indicate a severe differentiation deficit. (e) Fusion index of siRNA knocked down cells. (f) Myotube area of siRNA knocked down cells. (g) Number of myotube by field of siRNA knocked down cells. The fusion index was calculated as the ratio of the nuclei number in myotubes with two or more nuclei versus the total number of nuclei. Ten representative images per sample were scored for myotube number and area occupied by myotubes relative to the total area ( a p<0.05 vs Control). Fluorescence images showing reduced expression of eMHC after siRNA knock down for MuRF1 (k‐m) MuRF2 (n‐p) and MuRF1 and MuRF2 combined (q‐s) compared to control (h‐j). Images were obtained with a fluorescence microscope. Bars, 20 µm

    Article Snippet: The primary antibodies used for western blot were: (1) MuRF1 and (2) MuRF2 [27, 32]; (2) Atrogin/Mafbx‐1 (Cat#AP2041, ECM Biosciences); (3) Myf‐5 (Cat#sc‐302, Santa Cruz); (4) Myogenin (Cat#ab1835, Abcam); (5) sarcomeric actin (Cat#M0847, Dako); (6) GAPDH (Cat# 2118, CellSignaling), (7) FHL2 (Cat# A300‐332A, Bethyl Laboratories); (8) MARP2; (9) BAF57 (Cat#Abd52, Millipore).

    Techniques: Knockdown, Control, Fluorescence, Expressing, Microscopy

    Fig. 7 siRNA knock down of MuRF1 and MuRF2 reduce MyoD positive cell number. Cells were siRNA knocked down for MuRF1 (e‐h), MuRF2 (i‐l) and MuRF1 and MuRF2 combined (m‐p). Immunoflurescence for Pax7 (red) and MyoD (green) and dapi staining was performed. (q) Percentage of positive nuclei for MyoD. (r) Percentage of positive nuclei for Pax7. (s) Percentage of positive nuclei for Pax7 and MyoD. Ten representative images per group were scored for percentage of positive nuclei (*p<0.05 vs Control). Images were obtained with a fluorescence microscope and a 40x air medium objective. Bar, 30 µm

    Journal: JCSM Rapid Communications

    Article Title: MuRF1 and MuRF2 are key players in skeletal muscle regeneration involving myogenic deficit and deregulation of the chromatin-remodeling complex

    doi: 10.1002/j.2617-1619.2019.tb00010.x

    Figure Lengend Snippet: Fig. 7 siRNA knock down of MuRF1 and MuRF2 reduce MyoD positive cell number. Cells were siRNA knocked down for MuRF1 (e‐h), MuRF2 (i‐l) and MuRF1 and MuRF2 combined (m‐p). Immunoflurescence for Pax7 (red) and MyoD (green) and dapi staining was performed. (q) Percentage of positive nuclei for MyoD. (r) Percentage of positive nuclei for Pax7. (s) Percentage of positive nuclei for Pax7 and MyoD. Ten representative images per group were scored for percentage of positive nuclei (*p<0.05 vs Control). Images were obtained with a fluorescence microscope and a 40x air medium objective. Bar, 30 µm

    Article Snippet: The primary antibodies used for western blot were: (1) MuRF1 and (2) MuRF2 [27, 32]; (2) Atrogin/Mafbx‐1 (Cat#AP2041, ECM Biosciences); (3) Myf‐5 (Cat#sc‐302, Santa Cruz); (4) Myogenin (Cat#ab1835, Abcam); (5) sarcomeric actin (Cat#M0847, Dako); (6) GAPDH (Cat# 2118, CellSignaling), (7) FHL2 (Cat# A300‐332A, Bethyl Laboratories); (8) MARP2; (9) BAF57 (Cat#Abd52, Millipore).

    Techniques: Knockdown, Staining, Control, Fluorescence, Microscopy

    Fig. 8 siRNA knock down of MuRF1 and MuRF2 induce accumulation of BAF57 in the nucleus of primary myoblasts culture 2 days after induction of differentiation. (a‐j) Immunolocalization of BAF57 in cells siRNA knocked down for MuRF1 (c and d), MuRF2 (e and f) and MuRF1 and MuRF2 combined (g and h). (i) Representative immunoblots for BAF57 and GAPDH in cytoplasmic fraction from cells siRNA knocked down for MuRF1 (MuRF1 RNAi), MuRF2 (MuRF2 RNAi) and MuRF1 and MuRF2 combined (MuRF1/2 RNAi). (j) Representative immunoblots for BAF57 and GAPDH in nuclear fraction from cells siRNA knocked down for MuRF1 (MuRF1 RNAi), MuRF2 (MuRF2 RNAi) and MuRF1 and MuRF2 combined (MuRF1/2 RNAi). Bar, 40 µm

    Journal: JCSM Rapid Communications

    Article Title: MuRF1 and MuRF2 are key players in skeletal muscle regeneration involving myogenic deficit and deregulation of the chromatin-remodeling complex

    doi: 10.1002/j.2617-1619.2019.tb00010.x

    Figure Lengend Snippet: Fig. 8 siRNA knock down of MuRF1 and MuRF2 induce accumulation of BAF57 in the nucleus of primary myoblasts culture 2 days after induction of differentiation. (a‐j) Immunolocalization of BAF57 in cells siRNA knocked down for MuRF1 (c and d), MuRF2 (e and f) and MuRF1 and MuRF2 combined (g and h). (i) Representative immunoblots for BAF57 and GAPDH in cytoplasmic fraction from cells siRNA knocked down for MuRF1 (MuRF1 RNAi), MuRF2 (MuRF2 RNAi) and MuRF1 and MuRF2 combined (MuRF1/2 RNAi). (j) Representative immunoblots for BAF57 and GAPDH in nuclear fraction from cells siRNA knocked down for MuRF1 (MuRF1 RNAi), MuRF2 (MuRF2 RNAi) and MuRF1 and MuRF2 combined (MuRF1/2 RNAi). Bar, 40 µm

    Article Snippet: The primary antibodies used for western blot were: (1) MuRF1 and (2) MuRF2 [27, 32]; (2) Atrogin/Mafbx‐1 (Cat#AP2041, ECM Biosciences); (3) Myf‐5 (Cat#sc‐302, Santa Cruz); (4) Myogenin (Cat#ab1835, Abcam); (5) sarcomeric actin (Cat#M0847, Dako); (6) GAPDH (Cat# 2118, CellSignaling), (7) FHL2 (Cat# A300‐332A, Bethyl Laboratories); (8) MARP2; (9) BAF57 (Cat#Abd52, Millipore).

    Techniques: Knockdown, Western Blot